作为心力衰竭临床试验的终点,膜过率的下降:挑战和解决方案
Lesley A Inker1, Brendon L Neuen2, Wendy McCallum1
1Division of Nephrology, Tufts Medical Center, 800 Washington Street, Box #391, Boston 02111, MA, USA.
European heart journal
|September 4, 2025
概括
评估慢性病 (CKD) 在心力衰竭患者的进展需要了解膜过率 (GFR) 的变化. 早期的CKD进展终点对于试验至关重要,但解释即时GFR下降与长期益处是关键.
科学领域:
- 科和心脏病学
- 心血管代谢综合征
- 临床试验的终点
背景情况:
- 慢性病 (CKD) 和心血管疾病 (CVD) 具有共同的病理生理机制,形成心血管--代谢综合征.
- 慢性脏病和心力衰竭 (HF) 经常同时存在,治疗策略重叠.
- 对于个体治疗和临床试验评估来说,准确评估HF患者的慢性病进展至关重要.
研究的目的:
- 探索评估HF患者慢性瘤进展的方法,重点关注早期代用终点.
- 评估膜过率 (GFR) 变化作为HF结果试验的终点.
- 在HF治疗中解释GFR波动的挑战.
主要方法:
- 对CKD进展和HF结果的现有文献的审查.
- 分析慢性病进展的替代终点,包括GFR斜率和值下降.
- 通过案例研究讨论使用GFR作为HF试验的终点的挑战和可能的解决方案.
主要成果:
- 在试验中,通过斜率或百分比降低来测量膜过率 (GFR) 的下降是认可的CKD进展的替代终点.
- 随着指导性HF治疗,GFR可能会立即降低,从而使长期益处的评估变得复杂.
- 仔细解释GFR变化对于评估HF试验终点和患者管理至关重要.
结论:
- 在HF结局试验中,GFR变化为CKD进展提供了有价值的早期终点.
- 区分短暂的GFR下降和持续下降对于准确的评估至关重要.
- 对GFR终点的标准化解释将促进HF患者的护理和临床试验设计.
相关概念视频
01:02Renal Drug Excretion: Glomerular Filtration
490
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production occurs. A nephron has two main components: a renal corpuscle and a renal tubule.
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
490
01:17Factors Affecting Renal Clearance: Renal Impairment
154
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
154
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:11Renal Failure: Dose Adjustments
151
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
151